Babies under one year who catch hepatitis B are the most likely to develop chronic hepatitis B, which can lead to liver disease and liver cancer in adulthood. Babies are most at risk of catching hepatitis B at birth, which is why it is recommended that all babies are vaccinated against hepatitis B in the first 24 hours after being born. In Australia, the vaccine is free for all newborn babies.
Hepatitis B vaccine
What is hepatitis B?
Hepatitis B is a serious infectious disease caused by the hepatitis B virus (HBV). It mainly affects the liver1. It passes from person to person through blood and body fluids, and can be passed from a mother to a child at birth or soon after.
Some people infected with the hepatitis B virus experience mild flu-like symptoms; some experience more severe symptoms including fever, nausea and vomiting, pain in the liver, pain in the joints and yellowing of the skin (called ‘jaundice’).
However some people develop chronic hepatitis B, a condition that can lead to liver disease and liver cancer. The risk of developing chronic hepatitis B is greatest in babies1: around 90 per cent of babies who catch hepatitis B at birth develop chronic hepatitis B2.
Hepatitis B is highly contagious. You can be infected if you come into contact with blood or other body fluids from someone who carries the virus, even if that person shows no signs of illness. The greatest risk of infection occurs at birth when a mother who carries the virus can pass it on to her baby1.
Infection can also occur:
- during breastfeeding, if the mother carries the virus
- when adults or children come into contact with the open sores or cuts of an infected adult or child
- when adults or children share certain personal items with an infected person, such as a tooth brush
- when adults or children eat or share food that has been chewed or sucked by an infected person
- when adults or children are bitten by an infected person
- as a result of sharing needles or a needle stick injury
- when someone has unprotected sex with an infected person.
The virus can survive on objects for up to seven days, so infection can occur a number of days after an adult or child has been in contact with someone who carries the virus.
The hepatitis B virus is highly infectious and is 50 to 100 times more infectious than HIV, the human immunodeficiency virus that causes AIDS3.
The risks associated with hepatitis B are much greater for babies than they are for adults. Around 90 per cent of babies who catch hepatitis B at birth develop chronic hepatitis B. (Less than 10 per cent of adults who get the infection develop chronic hepatitis B2.)
- There is no cure for chronic hepatitis B infection.
- People with chronic hepatitis B need long-term antiviral therapy to reduce the risk of developing liver cancer4.
Around one in four babies who catch hepatitis B at birth or soon after will die of liver failure or liver cancer as an adult5.
Most adults who are infected with the hepatitis B virus recover fully. While infected, they may have no symptoms at all or very mild flu-like symptoms, or they may suffer from fever, nausea and vomiting, pain in the liver, pain in the joints and yellowing of the skin (called ‘jaundice’). Around 10 per cent of adults with a hepatitis B infection develop chronic hepatitis B which can lead to liver disease and liver cancer2.
In 2013 there were around 210,000 people living with chronic hepatitis B, and around 389 deaths related to chronic hepatitis B6. Overall, hepatitis B is not as common in Australia as it is in some other countries, however it is more common within some groups including Aboriginal and Torres Strait Islander communities.
How can I protect my baby from hepatitis B?
Vaccination is the most effective way to protect your baby from hepatitis B. The highest risk period for babies is at birth1. Many people who are carrying hepatitis B don’t know that they have the virus. Even mothers who have been tested during their pregnancy may have become infected since they were tested, so it is recommended that babies have their first dose of the hepatitis B vaccine within 24 hours of being born. Further doses are recommended at six weeks, four months and six months of age1.
Between 90 and 95 per cent of people under 40 who have had three doses of the hepatitis B vaccine, as recommended in the National Immunisation Program, are protected against the hepatitis B virus7.
What is the hepatitis B vaccine and how effective is it?
In Australia, the hepatitis B vaccine is given in four doses across the first year of life: at birth, and then at six weeks, four months and six months1. Hepatitis B vaccination for babies has been part of the National Immunisation Program since 2000. Different vaccination schedules are recommended for older children, teenagers and adults.
The vaccine works by training your baby’s immune system to recognise and get rid of the hepatitis B virus. The vaccine contains ‘antigens’ which are tiny fragments of the hepatitis B virus. When your baby’s immune system detects the antigens in the vaccine, it produces antibodies to fight them and get rid of them.
Hepatitis B is a viral infection and the antigen in the hepatitis B vaccine is a tiny, synthetically made fragment of the virus. The vaccine does not contain any blood products and is not a ‘live’ vaccine. The synthetic fragments cannot reproduce themselves or cause disease.
Between 90 and 95 per cent of people under 40 who have had three doses of the hepatitis B vaccine, as recommended in the National Immunisation Program, are protected against the hepatitis B virus7.
Some lifestyle factors - including age, obesity, certain infectious diseases or a history of smoking - can impact on the effectiveness of the hepatitis B vaccine. Speak with your doctor if you have questions about how lifestyle factors could impact on the effectiveness of the vaccination for your baby, or anyone else in your family.
Is it safe to give the vaccine to a newborn baby?
Yes, the hepatitis B vaccine is safe for newborns.
- There is no evidence that the dose given at birth affects a mother and baby’s ability to breastfeed8,9.
- There is no evidence that the birth dose is associated with Sudden Unexpected Death in Infancy (SUDI) or Sudden Infant Death Syndrome (SIDS)10.
- There is no evidence that the birth dose is associated with autism11.
- The birth dose is not associated with an increased risk of fever8,9.
The birth dose is not associated with an increased need for medical investigations into serious infection or sepsis in newborns8,9.
Premature babies are even more vulnerable to infection than full-term babies. For that reason, it is just as important to give the hepatitis B vaccine to premature babies to protect them from this serious infection. Your doctor or nurse can advise you on the best time for your baby to have their first dose of the vaccine, and whether an additional dose is required.
Will my baby have a reaction to the vaccine?
Most babies who have the hepatitis B vaccine at birth have only very mild reactions such as some redness, soreness or swelling at the spot where the needle went in8.
KEY FACTS
Your baby is most at risk of catching hepatitis B infection at birth.
Catching hepatitis B at birth leads to chronic infection in about 90 per cent of babies.
One in four chronically infected babies die of liver failure or liver cancer as an adult.
Most babies with a hepatitis B infection don’t show symptoms, so you may not know if your baby has an infection at birth or in the first few months of life.
Hepatitis B vaccine can protect your baby.
The hepatitis B vaccine is a safe vaccine for newborns.
- NCIRS. Hepatitis B vaccines for Australians. Westmead NSW: National Centre for Immunisation Research and Surveillance; 2015 [updated July 2015; cited 6 September 2018]. Available from: http://www.ncirs.edu.au/assets/provider_resources/fact-sheets/hepatitis-B-fact-sheet.pdf
- Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci. 1993;253:197-201.
- WHO. Hepatitis B: How can I protect myself? World Health Organization; 2015 [updated July 2015; cited 6 September 2018]. Available from: http://www.who.int/features/qa/11/en/
- Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. Journal of Hepatology. 2010;53:348-56.
- Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiologic Reviews. 2006;28:112-25.
- MacLachlan JH, Allard N, Towell V, Cowie BC. The burden of chronic hepatitis B virus infection in Australia, 2011. Australian and New Zealand Journal of Public Health. 2013;37:416-22.
- Van Damme P, Ward J, Shouval D, Wiersma S, Zanetti A. Hepatitis B vaccines. In: Plotkin SA, Orenstein WA, Offit PA (editors). Vaccines. 6th edition. Philadelphia, PA: Elsevier Saunders; 2013. p. 205-34.
- Lewis E, Shinefield HR, Woodruff BA, Black SB, Destefano F, Chen RT, et al. Safety of neonatal hepatitis B vaccine administration. Pediatric Infectious Disease Journal. 2001;20:1049- 54.
- Eriksen EM, Perlman JA, Miller A, Marcy SM, Lee H, Vadheim C, et al. Lack of association between hepatitis B birth immunization and neonatal death: a population-based study from the Vaccine Safety Datalink Project. Pediatric Infectious Disease Journal. 2004;23:656-61.
- Institute of Medicine (US) Immunization Safety Review Committee. Immunization Safety Review: Vaccinations and Sudden Unexpected Death in Infancy. Washington, DC: National Academies Press, 2003.
- Taylor LE, Swerdfeger AL, Eslick GD. Vaccines are not associated with autism: An evidence-based meta-analysis of case-control and cohort studies. Vaccine. 2014;32(29):3623-9.